FDA Approvals, Completed Tender Offers, Hospital Ratings, Trial Study Results,
and Stock Price Movements - Research Report on Pfizer, Amgen, Cigna, Hologic,
and Insys Therapeutics
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, October 9, 2013
NEW YORK, October 9, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Amgen, Inc. (NASDAQ: AMGN), Cigna Corporation (NYSE: CI),
Hologic, Inc. (NASDAQ: HOLX), and Insys Therapeutics Inc. (NASDAQ: INSY).
Today's readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.
Pfizer Inc. Research Report
On October 3, 2013, Pfizer Inc. (Pfizer) announced that it has received U.S.
Food and Drug Administration's (FDA) approval for DUAVEE^[^TM^] (conjugated
estrogens/bazedoxifene) 0.45mg/20mg tablets, for the treatment of
moderate-to-severe vasomotor symptoms associated with menopause and the
prevention of postmenopausal osteoporosis. The Company stated that when the
tablets are prescribed solely for the prevention of postmenopausal
osteoporosis, therapy should only be considered for women at significant risk
and non-estrogen medication should be carefully considered. The Company
reported that this approval of DUAVEE is the first in any country worldwide,
and anticipates it to be available in the US in Q1 2014. The Full Research
Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
Amgen, Inc. Research Report
On October 1, 2013, Amgen, Inc. (Amgen) announced that the Company has
completed its previously announced tender offer to purchase all outstanding
shares of common stock of Onyx Pharmaceuticals Inc. (Onyx) for $125 per share
in cash. The purchase price reported by the Company is $9.7 billion, net of
estimated Onyx cash. Amgen informed that the tender offer expired at 12:00
midnight New York City Time on October 1, 2013. According to the depositary
for the tender offer, approximately 57.7 million shares were validly tendered
and not withdrawn in the tender offer, representing approximately 78.5% of
Onyx's outstanding shares. Commenting on the acquisition, Robert A. Bradway,
Chairman and CEO of Amgen, said, "We look forward to working together with the
talented staff at Onyx to make the most of our exciting oncology portfolio and
pipeline." The Full Research Report on Amgen, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/e96b_AMGN]
Cigna Corporation Research Report
On October 3, 2013, Cigna Corporation (Cigna) announced that it is adding
Patient Experience ratings for hospitals across the country to its online
physician and hospital directory. Cigna claims that the information is
provided by the leading source of consumer information and recommendations,
and includes results from millions of patient surveys. The Company further
stated that the ratings include an overall patient rating that reflects
consumers' overall rating of the hospital and if they would recommend the
hospital to friends and family. The new patient experience ratings are
available on myCigna.com to all its U.S. health plan customers. Commenting on
the innovative step taken by the Company, Jackie Aube, Vice President of
Product Development, Cigna, said, "For a number of years we've been a leader
in providing our customers with reliable cost and quality information. Now
we're improving the customer experience by adding patient reviews that include
the aspects of care that are important to them." The Full Research Report on
Cigna Corporation - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
Hologic, Inc. Research Report
On October 2, 2013, Hologic, Inc. (Hologic) announced that the final analysis
of the American Society of Breast Surgeons (ASBS) MammoSite Breast
Brachytherapy Registry Trial data confirms previously noted "excellent"
results and compares favorably with other forms of accelerated partial breast
irradiation (APBI) and with outcomes seen in patients treated with whole
breast irradiation with similar follow-up. The Company stated that the final
analysis was published online before being printed in the August 22, 2013
issue of Annals of Surgical Oncology. Carter Houghton, Hologic's Senior Vice
President and General Manager, Interventional Breast Solutions, said, "The
acceptance of accelerated partial breast irradiation as an effective treatment
option for women diagnosed with early stage breast cancer continues to grow
worldwide due in part to the favorable results reported throughout this study.
Hologic's MammoSite Radiation Therapy is a compassionate treatment option that
allows women to return to their daily activities after just five days of
treatment, as compared to the conventional five to seven weeks, while
minimizing side effects such as skin burning and fatigue." The Full Research
Report on Hologic, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
Insys Therapeutics Inc. Research Report
On October 4, 2013, Insys Therapeutics Inc.'s (Insys Therapeutics) stock rose
sharply by 7.29%, ending the day at $44.15. Over the previous three trading
sessions, shares of Insys Therapeutics gained 20.99%, outperforming the Nasdaq
Composite which declined 0.27% during the same period. The Full Research
Report on Insys Therapeutics Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
are only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE Analysts' Corner
Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America
Press spacebar to pause and continue. Press esc to stop.